Gyre Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Gyre Pharmaceuticals at $32.4 million, 98% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
110
|
33
|
29
|
23
|
24
|
33
|
30
|
22
|
28
|
| Gyre Pharmaceuticals |
—
|
32
+6.1%
share 98.5%
|
29
+8.7%
share 100.0%
|
23
+2.1%
share 100.0%
|
37
+33.4%
share 157.7%
|
31
share 93.5%
|
27
share 90.0%
|
22
share 100.0%
|
28
share 100.0%
|
| Gyre |
—
|
1
-76.2%
share 1.5%
|
0
-99.7%
share 0.0%
|
—
|
—
|
2
share 6.5%
|
3
share 10.0%
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1124105
- Former names
- CATALYST BIOSCIENCES, INC. (until Oct 27, 2023); TARGACEPT INC (until Aug 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.